指南与共识血液净化与透析

生物标志物研究改善腹膜透析临床结局:EuTRiPD共识解读

Biomarker research to improve clinical outcomes of peritoneal dialysis: consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network.
指南 / 共识 · Kidney Int · 2017-08-08

欧洲腹膜透析培训与研究网络(EuTRiPD)发布共识,综述腹膜透析生物标志物研究现状。通过德尔菲法筛选出可作替代终点的现有标志物,并提名新型候选标志物用于概念验证研究。共识强调所有标志物与临床结局的关联仍需前瞻性独立研究验证。

要点

  • 现有标志物如IL-6、IL-8、CA-125和AOPP可作临床试验替代终点。
  • 新型候选标志物涵盖炎症、间皮细胞转化和衰老信号。
  • 所有标志物与临床结局的关联尚需严格验证。

核心结论

  • 腹膜透析生物标志物研究有望改善患者管理,但当前所有标志物与临床结局的关联仍需严格验证。

研究设计与样本

  • 欧洲腹膜透析培训与研究网络(EuTRiPD)成员发布的共识文章,基于文献综述和德尔菲法筛选标志物。

主要发现

  • 通过德尔菲法筛选出IL-6、IL-8、体外刺激IL-6释放、CA-125和AOPP作为临床试验替代终点候选。
  • 新型候选标志物分为炎症特征(IL-17、M1/M2巨噬细胞、Treg/Th17)、间皮细胞转化特征(miR-21、miR-31)和衰老与细胞应激反应特征。
  • 共识提出未来需利用腹透液和组学技术定义病原体特异性免疫指纹和表型相关分子特征。

关键数值与推荐

  • 现有标志物通过德尔菲法被分诊为临床试验替代终点候选。

临床怎么用

  • 腹透液中可直接检测的标志物(如IL-6、CA-125)可用于识别并发症高风险患者并指导个体化干预。

局限性

  • 所有标志物与临床结局的关联尚未在足够样本量的前瞻性独立临床研究中严格验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peritoneal dialysis (PD) therapy substantially requires biomarkers as tools to identify patients who are at the highest risk for PD-related complications and to guide personalized interventions that may improve clinical outcome in the individual patient. In this consensus article, members of the European Training and Research in Peritoneal Dialysis Network (EuTRiPD) review the current status of biomarker research in PD and suggest a selection of biomarkers that can be relevant to the care of PD patients and that are directly accessible in PD effluents. Currently used biomarkers such as interleukin-6, interleukin-8, ex vivo-stimulated interleukin-6 release, cancer antigen-125, and advanced oxidation protein products that were collected through a Delphi procedure were first triaged for inclusion as surrogate endpoints in a clinical trial. Next, novel biomarkers were selected as promising candidates for proof-of-concept studies and were differentiated into inflammation signatures (including interleukin-17, M1/M2 macrophages, and regulatory T cell/T helper 17), mesothelial-to-mesenchymal transition signatures (including microRNA-21 and microRNA-31), and signatures for senescence and inadequate cellular stress responses. Finally, the need for defining pathogen-specific immune fingerprints and phenotype-associated molecular signatures utilizing effluents from the clinical cohorts of PD patients and "omics" technologies and bioinformatics-biostatistics in future joint-research efforts was expressed. Biomarker research in PD offers the potential to develop valuable tools for improving patient management. However, for all biomarkers discussed in this consensus article, the association of biological rationales with relevant clinical outcomes remains to be rigorously validated in adequately powered, prospective, independent clinical studies.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Aufricht C, Beelen R, Eberl M, et al. Biomarker research to improve clinical outcomes of peritoneal dialysis: consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network. Kidney Int. 2017. PMID: 28797473. doi:10.1016/j.kint.2017.02.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。